Merrill Lynch keeps Amylin at sell rating

Amylin Pharmaceuticals Inc. was maintained by Merrill Lynch analyst Thomas McGahren at a sell rating as there is no change to estimates on top-line data for Byetta in combination with oral thiazolidinediones in patients with Type 2 diabetes. Merrill Lynch said the stock is pricey at current levels, even assuming generous peak sale estimates. Shares of the San Diego drug maker were up 68 cents, or 1.99%, at $34.89 on volume of 2,445,740 shares versus the three-month running average of 3,497,420 shares.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.